Protein needs should be individualized, with general targets of 1.2-1.6 g/kg body weight for many adults, though lower amounts may be appropriate for those with chronic kidney disease or other conditions requiring protein modification
Post-marketing surveillance and real-world data Beyond clinical trials, post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has produced mixed but ultimately reassuring results
Stock # 004586, Jackson Laboratories, Bar Harbor, ME, USA) or pancreatic duodenal homeobox-1 (PDX1Cre
Long-term weight maintenance after GLP-1 and GIP agonist therapy
10.2174/092986712803414015 79 SikiricP.SeiwerthS.RucmanR.TurkovicB.RokotovD
The dual GIP/GLP-1 mechanism enhances insulin secretion in a glucose-dependent manner